• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Markets:
    Overview
    News
    Currencies
    International
    Treasuries

    Xeris Biopharma Holdings, Inc. - Common Stock (NQ:XERS)

    5.600 UNCHANGED
    Streaming Delayed Price Updated: 4:00 PM EDT, Mar 9, 2026 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 5.600
    Bid (Size) 5.500 (10,000)
    Ask (Size) 6.150 (100)
    Prev. Close 5.600
    Today's Range 5.600 - 5.600
    52wk Range 3.805 - 10.08
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    News headline image
    Xeris Biopharma (XERS) Q4 2025 Earnings Transcript ↗
    Xeris Biopharma (XERS) Q4 2025 Earnings Transcript 
    Via The Motley Fool
    Topics Intellectual Property
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges on Strong Q4 Earnings and Robust 2026 Outlook ↗
    Via Chartmill

    Performance

    YTD
    -23.8%
    -23.8%
    1 Month
    -19.5%
    -19.5%
    3 Month
    -19.9%
    -19.9%
    6 Month
    -27.9%
    -27.9%
    1 Year
    +22.0%
    +22.0%

    More News

    Read More
    News headline image
    Xeris Biopharma Reports Record Performance for Fourth Quarter and Full Year 2025 and Provides Full Year 2026 Guidance
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma Subsidiaries File Recorlev® Patent Infringement Lawsuit
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Earnings Scheduled For November 6, 2025 ↗
    Via Benzinga
    News headline image
    Earnings Scheduled For August 7, 2025 ↗
    Via Benzinga
    News headline image
    Xeris Biopharma to Report Full Year 2025 Financial Results and Provide Full Year 2026 Guidance on March 2, 2026
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Expects to Deliver Record Fourth Quarter and Full-Year 2025 Total Revenue
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Why Xeris Biopharma Stock Zoomed 7% Higher on Wednesday ↗
    Via The Motley Fool
    The market is filled with gapping stocks in Wednesday's session. ↗
    Via Chartmill
    News headline image
    Xeris Announces Notice of Allowance from U.S. Patent and Trademark Office for XP-8121 Patent Application
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma (XERS) Q3 2025 Earnings Transcript ↗
    Via The Motley Fool
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Posts Record Q3 2025 Revenue but Misses Analyst Estimates ↗
    Via Chartmill
    News headline image
    Xeris Biopharma Posts Record Financial Results for the Third Quarter 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report Third Quarter 2025 Financial Results on November 6, 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Announces Orange Book Listing of U.S. Patent for Recorlev®
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris (XERS) Q2 Revenue Jumps 49% ↗
    Via The Motley Fool
    News headline image
    Traders are paying attention to the gapping stocks in Thursday's session. ↗
    Via Chartmill
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) Surges 12% After Q2 Earnings Beat and Raised Revenue Guidance ↗
    Via Chartmill
    Topics Earnings
    News headline image
    Xeris Biopharma Reports Record Financial Results for the Second Quarter 2025 and Raises Full Year Revenue Guidance
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    Xeris Biopharma to Report Second Quarter 2025 Financial Results on August 7, 2025
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire
    News headline image
    XERIS BIOPHARMA HOLDINGS INC (NASDAQ:XERS) – A Strong Growth Candidate Meeting Minervini’s Criteria ↗
    Via Chartmill
    News headline image
    Xeris Unveils Strategy for Long-Term Growth and Value Creation at 2025 Analyst & Investor Day
    From Xeris Biopharma Holdings, Inc.
    Via Business Wire

    Frequently Asked Questions

    Is Xeris Biopharma Holdings, Inc. - Common Stock publicly traded?
    Yes, Xeris Biopharma Holdings, Inc. - Common Stock is publicly traded.
    What exchange does Xeris Biopharma Holdings, Inc. - Common Stock trade on?
    Xeris Biopharma Holdings, Inc. - Common Stock trades on the Nasdaq Stock Market
    What is the ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock?
    The ticker symbol for Xeris Biopharma Holdings, Inc. - Common Stock is XERS on the Nasdaq Stock Market
    What is the current price of Xeris Biopharma Holdings, Inc. - Common Stock?
    The current price of Xeris Biopharma Holdings, Inc. - Common Stock is 5.600
    When was Xeris Biopharma Holdings, Inc. - Common Stock last traded?
    The last trade of Xeris Biopharma Holdings, Inc. - Common Stock was at 03/09/26 04:00 PM ET
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the Privacy Policy and Terms Of Service.
    © 2025 FinancialContent. All rights reserved.